Rupatadine for the treatment of urticaria
| Autor: | Antonio Ferrannini, Elisabetta Di Leo, Gian Franco Calogiuri, Eustachio Nettis, Angelo Vacca, Pantalea Delle Donne |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pharmacology
Constipation Urticaria business.industry Sedation medicine.medical_treatment Rupatadine Cyproheptadine Histamine Antagonists General Medicine Cold urticaria medicine.disease Erectile dysfunction Tolerability Anesthesia medicine Animals Humans Pharmacology (medical) Antihistamine Platelet Activating Factor medicine.symptom business Somnolence medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 14:1807-1813 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.2013.813481 |
| Popis: | Rupatadine fumarate is a second-generation antihistamine provided with a potent, long-lasting and balanced in vivo dual platelet-activating factor (PAF) and histamine antagonist activity and it uniquely combines both activities at a high level of potency. Rupatadine has a rapid onset of action and a long-lasting effect, so a once-daily dosing is permitted, moreover is well tolerated by young adults and the elders. Rupatadine does not present the side effects of first-generation H1-antihistamines, such as somnolence, fatigue, headache, impaired memory and learning, sedation, increased appetite, dry mouth, dry eyes, visual disturbances, constipation, urinary retention and erectile dysfunction.This study evaluates the effectiveness and safety of rupatadine in chronic urticaria (CU) and acquired cold urticaria (ACU), through a systematic review of the literature.Patients affected by urticaria are often discouraged because frequently their disease does not recognize a cause and it is unresponsive to treatments. Patients can control their symptoms assuming second-generation H1-antihistamines, such as rupatadine. Several randomized, double-blind, placebo-controlled trials testify effectiveness and safety of rupatadine in CU and ACU. However, further clinical trials to evaluate the efficacy of rupatadine in different urticaria subtypes and to test the safety of doses higher than 20 mg are encouraged. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|